Dublin, May 15, 2025 (GLOBE NEWSWIRE) — The “Nivolumab Market Report 2025” has been added to ResearchAndMarkets.com’s offering.
The nivolumab market has witnessed substantial growth, with its size rising from $1.69 billion in 2024 to an anticipated $1.94 billion in 2025 at a CAGR of 14.7%. This escalation is largely driven by advancements in immunotherapy, increasing cancer incidence, and successful clinical trials leading to regulatory approvals. Projected to reach $3.2 billion by 2029, the market is expected to grow at a CAGR of 13.4% due to the surge in personalized medicine, new indications for use, and enhanced global cancer care access.
One significant market trend is the focus on biomarker-driven treatments, neoantigen vaccines, and improved immunotherapy regimens. The rising prevalence of cancer significantly contributes to market expansion. For instance, the Australian Institute of Health and Welfare reported an increase in cancer diagnoses from 156,781 in 2021 to 160,570 in 2022. Nivolumab’s role in enabling the immune system to attack cancer cells underpins its growing importance in cancer treatment.
The prevalence of non-small cell lung cancer (NSCLC) serves as a critical factor in nivolumab’s market growth. NSCLC, which originates in lung epithelial cells, remains a significant focus. In March 2023, the American Society of Clinical Oncology estimated 238,340 new lung cancer diagnoses in the US, with NSCLC accounting for approximately 81%. These statistics highlight the potential growth for nivolumab applications in this domain.
Leading companies in the nivolumab market are prioritizing innovative drug development. Bristol-Myers Squibb Co., for example, received FDA approval in May 2022 for nivolumab-based regimens in advanced esophageal squamous cell carcinoma. Their partnership with China’s Lyvgen Biopharma in November 2022 aims to evaluate combination therapies targeting co-stimulatory and co-inhibitory checkpoints in immunotherapy-resistant diseases.
The competitive landscape includes Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., and others. North America dominated the market in 2024, with comprehensive coverage of regions like Asia-Pacific and Europe, and countries such as Australia, Brazil, China, Germany, India, Japan, and the USA.
Products available in the market include opdivo and generic nivolumab, primarily used in clinical settings for various cancer types. Nivolumab’s mechanisms enhance immune responses, proving critical in its application for melanoma, NSCLC, and renal cell carcinoma, among others. The industry continues to evolve with comprehensive market research, offering insights into market dynamics and future trajectories.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2025 – 2029 |
| Estimated Market Value (USD) in 2025 | $1.94 Billion |
| Forecasted Market Value (USD) by 2029 | $3.2 Billion |
| Compound Annual Growth Rate | 13.4% |
| Regions Covered | Global |
Key Topics Covered:
1. Executive Summary
2. Nivolumab Market Characteristics
3. Nivolumab Market Trends and Strategies
4. Nivolumab Market – Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market
5. Global Nivolumab Growth Analysis and Strategic Analysis Framework
- 5.1. Global Nivolumab PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis of End Use Industries
- 5.3. Global Nivolumab Market Growth Rate Analysis
- 5.4. Global Nivolumab Historic Market Size and Growth, 2019-2024, Value ($ Billion)
- 5.5. Global Nivolumab Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)
- 5.6. Global Nivolumab Total Addressable Market (TAM)
6. Nivolumab Market Segmentation
- 6.1. Global Nivolumab Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 6.2. Global Nivolumab Market, Segmentation by Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 6.3. Global Nivolumab Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 6.4. Global Nivolumab Market, Segmentation by End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 6.5. Global Nivolumab Market, Sub-Segmentation of Injection 4mL, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 6.6. Global Nivolumab Market, Sub-Segmentation of Injection 10mL, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7. Nivolumab Market Regional and Country Analysis
- 7.1. Global Nivolumab Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Nivolumab Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Companies Featured
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- AbbVie Inc.
- Novartis AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Amgen Inc.
- Regeneron Pharmaceuticals Inc.
- Astellas Pharma Inc.
- Chugai Pharmaceutical Co. Ltd.
- Daiichi Sankyo Company Limited
- Eisai Co. Ltd.
- Ono Pharmaceutical Co. Ltd.
- Kyowa Kirin Co. Ltd.
- Nippon Kayaku Co. Ltd.
- Luye Pharma AG
- Genentech Inc.
- Taiho Pharmaceutical Co. Ltd.
- SymBio Pharmaceuticals Ltd.
- Xbrane Biopharma AB
- NeuClone Therapeutics Inc.
For more information about this report visit https://www.researchandmarkets.com/r/q4abo1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
